GenoMed Chief Medical Officer to Present Data at Diabetes Meeting
ST. LOUIS, Oct. 24 /PRNewswire-FirstCall/ -- GenoMed, Inc. (OTC Pink Sheets: GMED) ("the Company" or "GenoMed"), a St. Louis, Missouri-based medical genomics biotechnology company, announced today that its Chairman and Chief Medical Officer, David Moskowitz, M.D., will be presenting the company's data at a conference next week.
Next Friday, November 1st, Dr. Moskowitz will present a poster at the Second Annual Diabetes Technology Meeting being held in Atlanta (www.diabetestechnology.org). His poster will be entitled "Improved Patient Outcomes Thanks to Medical Genomics: Diabetic Nephropathy in White and Black Men." The poster will describe kidney patients' outcomes using GenoMed's patent-pending treatment, which was published in the journal Diabetes Technology & Therapeutics on September 10th. Kidney failure could be slowed considerably if the treatment is begun early enough. Kidney failure could even be reversed if GenoMed's treatment was begun before a patient's serum creatinine, a common measure of kidney function, climbed past 2 milligrams per deciliter.
The poster will also present what other complications of type 1 and type 2 diabetes, in addition to kidney failure, might benefit from GenoMed's treatment. These include heart disease, stroke, poor circulation of the legs which often leads to amputations, eye damage that often leads to blindness ("retinopathy"), and numbness ("neuropathy"). The evidence for these additional disease targets was published yesterday in the same journal, Diabetes Technology & Therapeutics. No clinical results are yet available for these additional diseases associated with diabetes.
Dr. Moskowitz commented, "True to everyone's expectations, medical genomics is presenting us with a cornucopia of clinical solutions. What may be surprising to most people is that the clinical pay-off is already here, not a decade or two in the future."
Dr. Moskowitz continued, "It will take years of ongoing clinical research, of course, to find out exactly how rich a jackpot GenoMed has already hit. We know our ACE inhibitor treatment can prevent diabetic kidney disease, if started early enough. We need more experience with patients to know if the same treatment will also delay or even prevent other complications of diabetes. Given how awful diabetes still is, and given how safe and effective our ACE inhibitor treatment already is, I see little reason why a patient with diabetes wouldn't consider joining our Clinical Outcomes Improvement Program(TM) to try to prevent most complications of diabetes."
GenoMed, Inc. is a medical genomics company whose mission is to improve patient outcomes by identifying the genes that cause disease. A recent St. Louis Business Journal article (http://www.stlouis.bizjournals.com/stlouis/stories/2002/05/13/story8.html) reported that the company has applied for patents based on its finding that the ACE gene is associated with over 40 common, age-related diseases. The Company has filed patent applications on its new treatments for both human and veterinary use.
For questions, please contact Krissy Fischer, tel. 1-877-GENOMED (1-877-436-6633), FAX 314-977-0042, email: kfischer@genomedics.com, or visit GenoMed at www.genomedics.com.
SOURCE GenoMed, Inc.
CONTACT: Krissy Fischer of GenoMed, Inc., +1-877-GENOMED, or
+1-877-436-6633, or fax, +1-314-977-0042, or kfischer@genomedics.com
Web site: genomedics.com
. |
